Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis.
Akalin
Enver
E
Bromberg
Jonathan S
JS
Sehgal
Vinita
V
Ames
Scott
S
Murphy
Barbara
B
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000453:epidemiology*; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects* / Q000379:methods*; D013997:Time Factors; D000077562:Valganciclovir
D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir